Mona Dhiraj Shah, MD
Pediatric Hematology-Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Shah’s office at (650) 497-8000 to ask if they take your plan before you enroll.
California Medical Board record
Licence C177583 · Current
Licensed to practise in California · since 2022 · expires 2028-04-30 · University of Maryland School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatric Hematology-Oncology
- American Board of Pediatrics - Pediatrics
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 12 Part D prescriptions in 2020. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2020 | 12 | None | 0% (0) | 0% | $178 |
| 2019 | 30 | None | 0% (0) | 0% | $827 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2020: 1 drug
| Enoxaparin | 11 | $167 | $15 |
2019: 1 drug
| Enoxaparin | 30 | $827 | $28 |
Money from drug and device companies
$402 in 2021
| 2021 | 2 | 3 | None | $402 |
| 2019 | 2 | 4 | None | $513 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merz North America | None | $287 | 2 payments
|
| Boston Scientific | General Therapies | $116 | 1 payment
|
See all 3 published payments
| Merz North America | Meals · 2021-06-08 | None | $152 |
| Merz North America | Meals · 2021-05-28 | None | $135 |
| Boston Scientific | Meals · 2021-05-21 | General Therapies | $116 |
See earlier years (2019)
2019: $513
| Genentech | None | $379 | 2 payments
|
| Merz North America | Xeomin | $134 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novo Nordisk AS · 2019 | Their institution | $19,310 |
| Shire North American Group Inc · Phase 3, Prospective, Multi-Center, Open Label Study To Investigate Safety, Immunogenicity, and Hemostatic Efficacy of Pegylated Factor Viii Bax 855 in Previously Untreated Patients Pups and Minimally Treated Patients Mtps 6 Years With Severe Hemophilia A Fviii 1 · 2019 | Their institution | $4,660 |
| Takeda Pharmaceuticals U.S.A., Inc. · Phase 3, Prospective, Multi-Center, Open Label Study To Investigate Safety, Immunogenicity, and Hemostatic Efficacy of Pegylated Factor Viii (Bax 855) in Previously Untreated Patients (Pups) and Minimally Treated Patients (Mtps) < 6 Years With Severe Hemophilia A (Fviii < 1%) · 2020 | Their institution | $1,560 |
Professional record
- NPI
- 1669670253
- Licence
- CA C177583California C177583: Current · expires 2028-04-30
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2007-07-05
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.